ArticleInternational journal of clinical oncology2024

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of elranatamab for multiple myeloma, CPX-351 for myeloid leukemia, inotuzumab ozogamicin for lymphoblastic leukemia, capivasertib for breast cancer, and zolbetuximab for gastric cancer in Japan.

Noriomi Matsumura et al.PubMed ↗Publisher ↗

No numbers read from the abstract.